

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81922

Title: Systemic treatment for metastatic colorectal cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06272301

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Thailand

Manuscript submission date: 2022-11-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-29 12:07

Reviewer performed review: 2022-12-04 16:28

Review time: 5 Days and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements	Conflicts-of-Interest: [] Yes [Y] No
------------	---------------------------------------

SPECIFIC COMMENTS TO AUTHORS

This article provides a systematic and detailed review of the treatment strategies and progress of mCRC, which is strongly supported by the results of many clinical trials and focuses on systemic treatment strategies for liver metastatic colorectal cancer. But there are a few caveats: 1. This paper focuses on treatment, but the charts in this paper are mainly about the risk factors and molecular mechanisms of mCRC. Is it possible to draw additional charts or tables to outline the treatment strategies mentioned in this paper? 2. The author mentioned the treatment for tumor microenvironment in the introduction, does it just mean immunotherapy? As far as I know, the immune system knowledge of tumor microenvironment is part of the tumor microenvironment, and there are other therapeutic modalities that may be affected by tumor microenvironment treatment of tumor, the author can appropriately add. In addition, does mCRC have other immunotherapeutic possibilities besides immuncheckpoint inhibitors and CAR T therapy (although it may not have been systematically validated in clinical trials)? 3. The author focuses on systemic treatment of liver metastatic colorectal cancer, but this is a direction of mCRC treatment. It may be more appropriate to discuss liver metastatic colorectal cancer after discussing the overall treatment of mCRC. At the same time, it is hoped that the author can discuss the treatment strategies especially for liver metastatic colorectal cancer in the conclusion. 4. The article is smooth in language, but contains some grammatical mistakes. For example, "harmatomatous" in "POLYPS" in "RISK FACTORS FOR COLORECTAL CANCER" seems to have a spelling mistake.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 81922

Title: Systemic treatment for metastatic colorectal cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05372567

Position: Editorial Board

Academic degree: MD

Professional title: Assistant Professor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: China

Author's Country/Territory: Thailand

Manuscript submission date: 2022-11-29

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2023-01-28 22:29

Reviewer performed review: 2023-01-30 03:10

Review time: 1 Day and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

It is a well-written manuscript, in which the authors reviewed systemic treatment for metastatic colorectal cancer, including chemotherapy, targeted therapy, and immunotherapy. Minor suggestions as follows. 1. Add more figures to make the manuscript more attractive and illustrative. 2. Tables could be added to help the readers have a good knowledge of the latest progress in chemotherapy, targeted therapy, and immunotherapy.